Find News Releases
Media Resources
- B-roll for Media
- Benchmarks
- Multicultural Media
- NCI Annual Fact Book
- NCI Dictionary of Cancer Terms
- Visuals Online
- The National Cancer Program
2013 Annual Plan and Budget Proposal
All News Releases
Ohio State study finds older and younger chronic leukemia patients may need different therapies
NCI Cancer Center News
(Posted: 12/13/2012) - Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Age is usually not considered when determining treatment for people with CLL, but this study indicates that older people with CLL may not respond as well to the therapy used for most patients.
Fred Hutchinson study suggests delaying childbirth may reduce the risk of an aggressive form of breast cancer in younger women
NCI Cancer Center News
(Posted: 12/13/2012) - Younger women who wait at least 15 years after their first menstrual period to give birth to their first child may reduce their risk of an aggressive form of breast cancer by up to 60 percent, according to a Fred Hutchinson Cancer Research Center study. The findings are published online in Breast Cancer Research and Treatment. The study is the first to look at how the interval between first menstrual period and age at first birth is related to the risk of this particular type of breast cancer. It is also the first study to look at the relationship between reproductive factors and breast cancer risk among premenopausal women, who have a higher risk of triple-negative and HER2-overexpressing breast cancer than postmenopausal women.
Baylor study finds vegetable compound could become ingredient to treating leukemia
NCI Cancer Center News
(Posted: 12/13/2012) - A concentrated form of a compound called sulforaphane found in broccoli and other cruciferous vegetables has been shown to reduce the number of acute lymphoblastic leukemia cells in the lab setting, said researchers at Baylor College of Medicine (home of the Dan L. Duncan Cancer Center). The findings appear in the current edition of PLOS ONE. The researchers focused on purified sulforaphane, a natural compound found in broccoli believed to have both preventive and therapeutic properties in solid tumors. Studies have shown that people who eat a diet rich in cruciferous vegetables have a lower risk of some cancers.
NCI Central Institutional Review Board Receives Accreditation
NCI News Note
(Posted: 12/12/2012) - The Association for the Accreditation of Human Research Protection Programs has awarded the NCI Central Institutional Review Board full accreditation. AAHRPP awards accreditation to organizations demonstrating the highest ethical standards in clinical research. Achieving accreditation establishes that the NCI CIRB has robust review processes in place to ensure the safety and protection of people who participate in NCI-funded clinical studies.
MD Anderson study finds weekly dose reduces a targeted drug's side effects but not its activity against acute lymphocytic leukemia
NCI Cancer Center News
(Posted: 12/12/2012) - A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ASH Annual Meeting and Exposition. This "Trojan horse" assault on the cancer cells has significantly increased the response rate among patients with ALL, and now an MD Anderson Cancer Center clinical trial finds that weekly dosing works well and reduces side effects.
Temple scientists find drug resistant stem cells may be source of genetic chaos, DNA damage in leukemia
NCI Cancer Center News
(Posted: 12/12/2012) - An international team of scientists, led by researchers from Temple University School of Medicine (home to the Fox Chase Cancer Center), has found that a source of mounting genomic chaos, or instability, common to chronic myeloid leukemia (CML) may lie in a pool of leukemia stem cells that are immune to treatment with potent targeted anticancer drugs. They have shown in mice with cancer that even after treatment with the highly effective imatinib (Gleevec), stem cells that become resistant to these drugs – tyrosine kinase inhibitors (TKIs) – may continue to foster DNA damage, potentially leading to disease relapse and a downward spiral to a much more deadly “blast” stage of leukemia.
Study identifies anti-aging gene as tumor suppressor in mice
NCI Cancer Center News
(Posted: 12/12/2012) - A new study sheds more light on how an anti-aging gene suppresses cancer growth, joint University of Michigan Health System (home to the University of Michigan Comprehensive Cancer Center) and Harvard Medical School (home to the Dana-Farber Cancer Institute) research shows. Loss of the SIRT6 protein in mice increases the number, size and aggressiveness of tumors, according to the new research published in the scientific journal Cell. The study also suggests that the loss of SIRT6 promotes tumor growth in human colon and pancreatic cancers.
Provocative Questions in Cancer Research: National Cancer Institute Science Writers’ Seminar
(Posted: 11/27/2012, Updated: 12/12/2012) - science writers' seminar to discuss various aspects of one of NCI’s signature efforts -- the Provocative Questions project. Discussion will focus on the scientific research that surrounds some of these questions.
Dana-Farber study finds blood levels of immune protein predict risk in Hodgkin disease
NCI Cancer Center News
(Posted: 12/11/2012) - Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting. In a study of 315 patients from a German database, researchers from Dana-Farber Cancer Institute found that serum galectin-1 levels "are significantly associated with tumor burden and additional adverse clinical characteristics in newly diagnosed Hodgkin lymphoma (HL) patients."
Dana-Farber researchers find experimental graft-versus-host disease treatment equivalent to standard care in phase 3 trial
NCI Cancer Center News
(Posted: 12/11/2012) - An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting. The combination of two immunosuppressive compounds – tacrolimus plus sirolimus – did not provide a statistically significant, GVHD-free survival benefit over the long-used standard of care, tacrolimus plus methotrexate, said researchers from Dana-Farber Cancer Institute who led the multi-center trial.
NCI Cancer Center News
(Posted: 12/13/2012) - Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Age is usually not considered when determining treatment for people with CLL, but this study indicates that older people with CLL may not respond as well to the therapy used for most patients.
Fred Hutchinson study suggests delaying childbirth may reduce the risk of an aggressive form of breast cancer in younger women
NCI Cancer Center News
(Posted: 12/13/2012) - Younger women who wait at least 15 years after their first menstrual period to give birth to their first child may reduce their risk of an aggressive form of breast cancer by up to 60 percent, according to a Fred Hutchinson Cancer Research Center study. The findings are published online in Breast Cancer Research and Treatment. The study is the first to look at how the interval between first menstrual period and age at first birth is related to the risk of this particular type of breast cancer. It is also the first study to look at the relationship between reproductive factors and breast cancer risk among premenopausal women, who have a higher risk of triple-negative and HER2-overexpressing breast cancer than postmenopausal women.
Baylor study finds vegetable compound could become ingredient to treating leukemia
NCI Cancer Center News
(Posted: 12/13/2012) - A concentrated form of a compound called sulforaphane found in broccoli and other cruciferous vegetables has been shown to reduce the number of acute lymphoblastic leukemia cells in the lab setting, said researchers at Baylor College of Medicine (home of the Dan L. Duncan Cancer Center). The findings appear in the current edition of PLOS ONE. The researchers focused on purified sulforaphane, a natural compound found in broccoli believed to have both preventive and therapeutic properties in solid tumors. Studies have shown that people who eat a diet rich in cruciferous vegetables have a lower risk of some cancers.
NCI Central Institutional Review Board Receives Accreditation
NCI News Note
(Posted: 12/12/2012) - The Association for the Accreditation of Human Research Protection Programs has awarded the NCI Central Institutional Review Board full accreditation. AAHRPP awards accreditation to organizations demonstrating the highest ethical standards in clinical research. Achieving accreditation establishes that the NCI CIRB has robust review processes in place to ensure the safety and protection of people who participate in NCI-funded clinical studies.
MD Anderson study finds weekly dose reduces a targeted drug's side effects but not its activity against acute lymphocytic leukemia
NCI Cancer Center News
(Posted: 12/12/2012) - A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ASH Annual Meeting and Exposition. This "Trojan horse" assault on the cancer cells has significantly increased the response rate among patients with ALL, and now an MD Anderson Cancer Center clinical trial finds that weekly dosing works well and reduces side effects.
Temple scientists find drug resistant stem cells may be source of genetic chaos, DNA damage in leukemia
NCI Cancer Center News
(Posted: 12/12/2012) - An international team of scientists, led by researchers from Temple University School of Medicine (home to the Fox Chase Cancer Center), has found that a source of mounting genomic chaos, or instability, common to chronic myeloid leukemia (CML) may lie in a pool of leukemia stem cells that are immune to treatment with potent targeted anticancer drugs. They have shown in mice with cancer that even after treatment with the highly effective imatinib (Gleevec), stem cells that become resistant to these drugs – tyrosine kinase inhibitors (TKIs) – may continue to foster DNA damage, potentially leading to disease relapse and a downward spiral to a much more deadly “blast” stage of leukemia.
Study identifies anti-aging gene as tumor suppressor in mice
NCI Cancer Center News
(Posted: 12/12/2012) - A new study sheds more light on how an anti-aging gene suppresses cancer growth, joint University of Michigan Health System (home to the University of Michigan Comprehensive Cancer Center) and Harvard Medical School (home to the Dana-Farber Cancer Institute) research shows. Loss of the SIRT6 protein in mice increases the number, size and aggressiveness of tumors, according to the new research published in the scientific journal Cell. The study also suggests that the loss of SIRT6 promotes tumor growth in human colon and pancreatic cancers.
Provocative Questions in Cancer Research: National Cancer Institute Science Writers’ Seminar
(Posted: 11/27/2012, Updated: 12/12/2012) - science writers' seminar to discuss various aspects of one of NCI’s signature efforts -- the Provocative Questions project. Discussion will focus on the scientific research that surrounds some of these questions.
Dana-Farber study finds blood levels of immune protein predict risk in Hodgkin disease
NCI Cancer Center News
(Posted: 12/11/2012) - Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting. In a study of 315 patients from a German database, researchers from Dana-Farber Cancer Institute found that serum galectin-1 levels "are significantly associated with tumor burden and additional adverse clinical characteristics in newly diagnosed Hodgkin lymphoma (HL) patients."
Dana-Farber researchers find experimental graft-versus-host disease treatment equivalent to standard care in phase 3 trial
NCI Cancer Center News
(Posted: 12/11/2012) - An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting. The combination of two immunosuppressive compounds – tacrolimus plus sirolimus – did not provide a statistically significant, GVHD-free survival benefit over the long-used standard of care, tacrolimus plus methotrexate, said researchers from Dana-Farber Cancer Institute who led the multi-center trial.
